Safety and Efficacy of Foscarnet for Preemptive Therapy Against Cytomegalovirus Reactivation After Unrelated Cord Blood Transplantation
Abstract In association with the increased use of unrelated cord blood transplantation (UCBT) in adults, numerous patients have developed cytomegalovirus (CMV) reactivation concomitant with cytopenia. Although foscarnet appears to offer similar efficacy and higher safety as a preemptive therapy agai...
Gespeichert in:
| Veröffentlicht in: | Transplantation proceedings 2007, Vol.39 (1), p.237-239 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 239 |
|---|---|
| container_issue | 1 |
| container_start_page | 237 |
| container_title | Transplantation proceedings |
| container_volume | 39 |
| creator | Takami, A Mochizuki, K Ito, S Sugimori, C Yamashita, T Asakura, H Okumura, H Nakao, S |
| description | Abstract In association with the increased use of unrelated cord blood transplantation (UCBT) in adults, numerous patients have developed cytomegalovirus (CMV) reactivation concomitant with cytopenia. Although foscarnet appears to offer similar efficacy and higher safety as a preemptive therapy against CMV infection than ganciclovir, little is known about the usefulness of foscarnet in such patients. Foscarnet was administered as preemptive therapy against CMV antigenemia in 10 UCBT recipients who were unable to receive ganciclovir due to cytopenia or poor response to ganciclovir. Fatal CMV disease developed in one patient, whereas CMV antigenemia resolved without progression to CMV disease in the remaining nine patients. Foscarnet was well tolerated without serious hematotoxicity and was not discontinued due to adverse events in any patient. Foscarnet represents a safe and effective agent for preemptive therapy against CMV infection and may offer a feasible alternative to ganciclovir in UCBT recipients. |
| doi_str_mv | 10.1016/j.transproceed.2006.10.191 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68986135</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0041134506014540</els_id><sourcerecordid>68986135</sourcerecordid><originalsourceid>FETCH-LOGICAL-c433t-55c4c568c073a797adc3e80144818a6c3ba8239084eeeac531e7b4b85a3016ba3</originalsourceid><addsrcrecordid>eNqNks2O0zAUhS0EYjoDr4AsFuxS7NhOHBZIpcwA0kggprO2HOdmcEntYjuV8gS89jhthRArVpZ1v_t3zkXoNSVLSmj1drtMQbu4D94AdMuSkGo5xxr6BC2orFlRViV7ihaEcFpQxsUFuoxxS_K_5Ow5uqB1WQtBywX6fad7SBPWrsPXfW-NNhP2Pb7x0ejgIOHeB_wtAOz2yR4Ab35A0PsJrx60dTHh9ZT8Dh704A82jBF_B20yqJP1Dq_6BAHfuwCDTtDhtQ8d_jB43-HNcYVBu3REX6BnvR4ivDy_V-j-5nqz_lzcfv30Zb26LQxnLBVCGG5EJQ2pma6bWneGgSSUc0mlrgxrtSxZQyQHyIMIRqFueSuFZlm5VrMr9OZUN6v3a4SY1M5GA0MeBPwYVSUbWVEmMvjuBJrgYwzQq32wOx0mRYmabVBb9bcNarbhGGtoTn517jK2uxz7k3rWPQMfTwDkXQ8WgorGgjPQ2QAmqc7b_-vz_p8yZrAumzj8hAni1o_BZTUVVbFURN3NBzHfA6myZIIT9giIireu</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68986135</pqid></control><display><type>article</type><title>Safety and Efficacy of Foscarnet for Preemptive Therapy Against Cytomegalovirus Reactivation After Unrelated Cord Blood Transplantation</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Takami, A ; Mochizuki, K ; Ito, S ; Sugimori, C ; Yamashita, T ; Asakura, H ; Okumura, H ; Nakao, S</creator><creatorcontrib>Takami, A ; Mochizuki, K ; Ito, S ; Sugimori, C ; Yamashita, T ; Asakura, H ; Okumura, H ; Nakao, S</creatorcontrib><description>Abstract In association with the increased use of unrelated cord blood transplantation (UCBT) in adults, numerous patients have developed cytomegalovirus (CMV) reactivation concomitant with cytopenia. Although foscarnet appears to offer similar efficacy and higher safety as a preemptive therapy against CMV infection than ganciclovir, little is known about the usefulness of foscarnet in such patients. Foscarnet was administered as preemptive therapy against CMV antigenemia in 10 UCBT recipients who were unable to receive ganciclovir due to cytopenia or poor response to ganciclovir. Fatal CMV disease developed in one patient, whereas CMV antigenemia resolved without progression to CMV disease in the remaining nine patients. Foscarnet was well tolerated without serious hematotoxicity and was not discontinued due to adverse events in any patient. Foscarnet represents a safe and effective agent for preemptive therapy against CMV infection and may offer a feasible alternative to ganciclovir in UCBT recipients.</description><identifier>ISSN: 0041-1345</identifier><identifier>EISSN: 1873-2623</identifier><identifier>DOI: 10.1016/j.transproceed.2006.10.191</identifier><identifier>PMID: 17275512</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Antigens, Viral - blood ; Antiviral Agents - therapeutic use ; Bone Marrow Transplantation ; Cord Blood Stem Cell Transplantation ; Cytomegalovirus Infections - prevention & control ; Foscarnet - therapeutic use ; Humans ; Leukocyte Count ; Neutrophils ; Patient Selection ; Recurrence ; Surgery ; Treatment Outcome</subject><ispartof>Transplantation proceedings, 2007, Vol.39 (1), p.237-239</ispartof><rights>Elsevier Inc.</rights><rights>2007 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c433t-55c4c568c073a797adc3e80144818a6c3ba8239084eeeac531e7b4b85a3016ba3</citedby><cites>FETCH-LOGICAL-c433t-55c4c568c073a797adc3e80144818a6c3ba8239084eeeac531e7b4b85a3016ba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.transproceed.2006.10.191$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,4024,27923,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17275512$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Takami, A</creatorcontrib><creatorcontrib>Mochizuki, K</creatorcontrib><creatorcontrib>Ito, S</creatorcontrib><creatorcontrib>Sugimori, C</creatorcontrib><creatorcontrib>Yamashita, T</creatorcontrib><creatorcontrib>Asakura, H</creatorcontrib><creatorcontrib>Okumura, H</creatorcontrib><creatorcontrib>Nakao, S</creatorcontrib><title>Safety and Efficacy of Foscarnet for Preemptive Therapy Against Cytomegalovirus Reactivation After Unrelated Cord Blood Transplantation</title><title>Transplantation proceedings</title><addtitle>Transplant Proc</addtitle><description>Abstract In association with the increased use of unrelated cord blood transplantation (UCBT) in adults, numerous patients have developed cytomegalovirus (CMV) reactivation concomitant with cytopenia. Although foscarnet appears to offer similar efficacy and higher safety as a preemptive therapy against CMV infection than ganciclovir, little is known about the usefulness of foscarnet in such patients. Foscarnet was administered as preemptive therapy against CMV antigenemia in 10 UCBT recipients who were unable to receive ganciclovir due to cytopenia or poor response to ganciclovir. Fatal CMV disease developed in one patient, whereas CMV antigenemia resolved without progression to CMV disease in the remaining nine patients. Foscarnet was well tolerated without serious hematotoxicity and was not discontinued due to adverse events in any patient. Foscarnet represents a safe and effective agent for preemptive therapy against CMV infection and may offer a feasible alternative to ganciclovir in UCBT recipients.</description><subject>Antigens, Viral - blood</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Bone Marrow Transplantation</subject><subject>Cord Blood Stem Cell Transplantation</subject><subject>Cytomegalovirus Infections - prevention & control</subject><subject>Foscarnet - therapeutic use</subject><subject>Humans</subject><subject>Leukocyte Count</subject><subject>Neutrophils</subject><subject>Patient Selection</subject><subject>Recurrence</subject><subject>Surgery</subject><subject>Treatment Outcome</subject><issn>0041-1345</issn><issn>1873-2623</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNks2O0zAUhS0EYjoDr4AsFuxS7NhOHBZIpcwA0kggprO2HOdmcEntYjuV8gS89jhthRArVpZ1v_t3zkXoNSVLSmj1drtMQbu4D94AdMuSkGo5xxr6BC2orFlRViV7ihaEcFpQxsUFuoxxS_K_5Ow5uqB1WQtBywX6fad7SBPWrsPXfW-NNhP2Pb7x0ejgIOHeB_wtAOz2yR4Ab35A0PsJrx60dTHh9ZT8Dh704A82jBF_B20yqJP1Dq_6BAHfuwCDTtDhtQ8d_jB43-HNcYVBu3REX6BnvR4ivDy_V-j-5nqz_lzcfv30Zb26LQxnLBVCGG5EJQ2pma6bWneGgSSUc0mlrgxrtSxZQyQHyIMIRqFueSuFZlm5VrMr9OZUN6v3a4SY1M5GA0MeBPwYVSUbWVEmMvjuBJrgYwzQq32wOx0mRYmabVBb9bcNarbhGGtoTn517jK2uxz7k3rWPQMfTwDkXQ8WgorGgjPQ2QAmqc7b_-vz_p8yZrAumzj8hAni1o_BZTUVVbFURN3NBzHfA6myZIIT9giIireu</recordid><startdate>2007</startdate><enddate>2007</enddate><creator>Takami, A</creator><creator>Mochizuki, K</creator><creator>Ito, S</creator><creator>Sugimori, C</creator><creator>Yamashita, T</creator><creator>Asakura, H</creator><creator>Okumura, H</creator><creator>Nakao, S</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2007</creationdate><title>Safety and Efficacy of Foscarnet for Preemptive Therapy Against Cytomegalovirus Reactivation After Unrelated Cord Blood Transplantation</title><author>Takami, A ; Mochizuki, K ; Ito, S ; Sugimori, C ; Yamashita, T ; Asakura, H ; Okumura, H ; Nakao, S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c433t-55c4c568c073a797adc3e80144818a6c3ba8239084eeeac531e7b4b85a3016ba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Antigens, Viral - blood</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Bone Marrow Transplantation</topic><topic>Cord Blood Stem Cell Transplantation</topic><topic>Cytomegalovirus Infections - prevention & control</topic><topic>Foscarnet - therapeutic use</topic><topic>Humans</topic><topic>Leukocyte Count</topic><topic>Neutrophils</topic><topic>Patient Selection</topic><topic>Recurrence</topic><topic>Surgery</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Takami, A</creatorcontrib><creatorcontrib>Mochizuki, K</creatorcontrib><creatorcontrib>Ito, S</creatorcontrib><creatorcontrib>Sugimori, C</creatorcontrib><creatorcontrib>Yamashita, T</creatorcontrib><creatorcontrib>Asakura, H</creatorcontrib><creatorcontrib>Okumura, H</creatorcontrib><creatorcontrib>Nakao, S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transplantation proceedings</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Takami, A</au><au>Mochizuki, K</au><au>Ito, S</au><au>Sugimori, C</au><au>Yamashita, T</au><au>Asakura, H</au><au>Okumura, H</au><au>Nakao, S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and Efficacy of Foscarnet for Preemptive Therapy Against Cytomegalovirus Reactivation After Unrelated Cord Blood Transplantation</atitle><jtitle>Transplantation proceedings</jtitle><addtitle>Transplant Proc</addtitle><date>2007</date><risdate>2007</risdate><volume>39</volume><issue>1</issue><spage>237</spage><epage>239</epage><pages>237-239</pages><issn>0041-1345</issn><eissn>1873-2623</eissn><abstract>Abstract In association with the increased use of unrelated cord blood transplantation (UCBT) in adults, numerous patients have developed cytomegalovirus (CMV) reactivation concomitant with cytopenia. Although foscarnet appears to offer similar efficacy and higher safety as a preemptive therapy against CMV infection than ganciclovir, little is known about the usefulness of foscarnet in such patients. Foscarnet was administered as preemptive therapy against CMV antigenemia in 10 UCBT recipients who were unable to receive ganciclovir due to cytopenia or poor response to ganciclovir. Fatal CMV disease developed in one patient, whereas CMV antigenemia resolved without progression to CMV disease in the remaining nine patients. Foscarnet was well tolerated without serious hematotoxicity and was not discontinued due to adverse events in any patient. Foscarnet represents a safe and effective agent for preemptive therapy against CMV infection and may offer a feasible alternative to ganciclovir in UCBT recipients.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>17275512</pmid><doi>10.1016/j.transproceed.2006.10.191</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0041-1345 |
| ispartof | Transplantation proceedings, 2007, Vol.39 (1), p.237-239 |
| issn | 0041-1345 1873-2623 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68986135 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Antigens, Viral - blood Antiviral Agents - therapeutic use Bone Marrow Transplantation Cord Blood Stem Cell Transplantation Cytomegalovirus Infections - prevention & control Foscarnet - therapeutic use Humans Leukocyte Count Neutrophils Patient Selection Recurrence Surgery Treatment Outcome |
| title | Safety and Efficacy of Foscarnet for Preemptive Therapy Against Cytomegalovirus Reactivation After Unrelated Cord Blood Transplantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T06%3A30%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20Efficacy%20of%20Foscarnet%20for%20Preemptive%20Therapy%20Against%20Cytomegalovirus%20Reactivation%20After%20Unrelated%20Cord%20Blood%20Transplantation&rft.jtitle=Transplantation%20proceedings&rft.au=Takami,%20A&rft.date=2007&rft.volume=39&rft.issue=1&rft.spage=237&rft.epage=239&rft.pages=237-239&rft.issn=0041-1345&rft.eissn=1873-2623&rft_id=info:doi/10.1016/j.transproceed.2006.10.191&rft_dat=%3Cproquest_cross%3E68986135%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68986135&rft_id=info:pmid/17275512&rft_els_id=1_s2_0_S0041134506014540&rfr_iscdi=true |